Literature DB >> 9161800

Adjuvant therapy for melanoma.

V K Sondak1, J A Wolfe.   

Abstract

The search for effective adjuvant therapy for melanoma has resulted in the testing of a remarkably broad spectrum of therapeutic agents. Until recently, there was little evidence to suggest a benefit for any adjuvant therapy. The demonstration of activity for adjuvant high-dose interferon alfa in a cooperative group trial resulted in Food and Drug Administration approval and has dramatically changed the melanoma landscape. This article reviews all the randomized adjuvant trials conducted to date in melanoma, discusses pertinent studies still in progress or awaiting analysis, and offers recommendations for the adjuvant treatment of melanoma patients rendered clinically disease-free by surgery.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9161800     DOI: 10.1097/00001622-199703000-00015

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  4 in total

1.  A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon alpha.

Authors:  H M Horton; D Anderson; P Hernandez; K M Barnhart; J A Norman; S E Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

2.  A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire.

Authors:  F M Batliwalla; B A Bateman; D Serrano; D Murray; S Macphail; V C Maino; J C Ansel; P K Gregersen; C A Armstrong
Journal:  Mol Med       Date:  1998-12       Impact factor: 6.354

Review 3.  Melanoma: adjuvant therapy and other treatment options.

Authors:  Alicia Terando; Michael S Sabel; Vernon K Sondak
Journal:  Curr Treat Options Oncol       Date:  2003-06

4.  An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.

Authors:  Arielle G Bensimon; Zheng-Yi Zhou; Madeline Jenkins; Yan Song; Wei Gao; James Signorovitch; Clemens Krepler; Emilie Scherrer; Jingshu Wang; Raquel Aguiar-Ibáñez
Journal:  Clin Drug Investig       Date:  2020-07       Impact factor: 2.859

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.